Embryo development in rats treated with tacrolimus during the preimplantation phase;Desenvolvimento embrionário em ratas tratadas com tacrolimus durante a fase de pré-implantação

Revista Brasileira de Ginecologia e Obstetricia

Volumn 30, Issue 5, 2008, Pages 219-223

  Ramos, Alessanda Fernandez Louzada Hoegmann ^a   Rodrigues, Jhennifer Kliemchen ^a   Da Silva, Lorena Ribeiro ^a   Guerra, Martha De Oliveira ^a   Peters, Vera Maria ^a,b  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Universidade Federal de Juiz de Fora ^*  (Brazil)

Author keywords

Blastocyst; Embryonic structures drug effects; Immunosuppression; Rats, Wistar; Tacrolimus toxicity; Tracolimus administration dosage

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ANIMAL; ARTICLE; DRUG EFFECT; EMBRYO DEVELOPMENT; FEMALE; PREGNANCY; RAT; WISTAR RAT;

ANIMALS; EMBRYONIC DEVELOPMENT; FEMALE; IMMUNOSUPPRESSIVE AGENTS; PREGNANCY; RATS; RATS, WISTAR; TACROLIMUS;

EID: 51949091825     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Garcia SC, Lopes LC, Schott KL. Cyclosporine A and tacrolimus: a review. J Bras Patol Med Lab. 2004;40(6):393-401.
2. Kaplan B, West P, Neeley H, Martellotto J, Iqbal R, Gangemi A, et al. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. Clin Transplant. 2008:22(2):250-3.
3. Prats CI, López de ACE, Herranz PP, Arranz SDM, Corral CM, Casado JM. Eficacia de tacrolimus tópico en el tratamiento del vitíligo. Med Cutan Iber Lat Am. 2005;33(4):171-4.
4. Taylor ALC, Watson CJ, Bradley JA. Immunosuppresive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56(1):23-46.
5. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22(1):1-15.
6. Satchell S, Moppett J, Quinn M, Nicholls A. Pregnancy, tacrolimus, and renal transplantation: survival of a 358-g baby. Nephrol Dial Transplant. 2000;15(12):2065-6.
7. Danesi R, Del Tacca M. Teratogenesis and immunosuppressive treatment. Transplant Proc. 2004;36(3):705-7.
8. Jabiry-Zieniewicz Z, Kamiński P, Pietrzak B, Cyganek A, Bobrowska K, Ziółkowski J, et al. Outcome of four high-risk pregnancies in female liver transplant recipients on tacrolimus immunosuppression. Transplant Proc. 2006;38(1):255-7.
9. Christopher V, Al-Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl. 2006;12(7):1138-43.
10. Gutiérrez MJ, Acebedo-Ribó M, García-Donaire JA, Manzanera MJ, Molina A, González E, et al. Pregnancy in renal transplant recipients. Transplant Proc. 2005;37(9):3721-2.
11. Ducarme G, Théron-Gérard L, Duvoux C, Uzan M, Poncelet C. Pregnancy after liver transplantation with tacrolimus. Eur J Obstet Gynecol Reprod Biol. 2007;133(2):249-50.
12. Kainz A, Harabacz I, Colwrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13(Suppl 1):S299-00.
13. Albengres E, LeLouet H, Tillement JP. Immunosuppressive drugs and pregnancy: experimental clinical data. Transplant Proc. 1997;29(5):2461-6.
14. Gewirtz AT, Sitaraman SV. Tacrolimus fujisawa. Curr Opin Investig Drugs. 2002;3(9):1307-11.
15. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs. 2000;59(2):323-89.
16. Kita A, Sugiura R, Shogi H, He Y, Deng L, Lu Y, et al. Loss of Apm1, the micro1 subunit of the clathrin-associated adaptorprotein-1 complex, causes distinct phenotypes and synthetic lethality with calcineurin deletion in fission yeast. Mol Biol Cell 2004;15(6):2920-31.
17. Alikani M. Epithelial cadherin distribution in abnormal human pre-implantation embryos. Hum Reprod. 2005;20(12):3369-75.
18. Kawai Y, Yamaguchi T, Yoden T, Hanada M, Myake M. Effect of protein phosphatase inhibitors on the development of mouse embryos: protein phosphorylation is involved in the E-cadherin distribution in mouse two-cell embryos. Biol Pharm Bull. 2002;25(2):179-83.
19. Pinto RM, Fernandes ES, Reis JE, Peters VM, Guerra M de O. Intra-uterine growth retardation after prenatal administration of Ginkgo biloba to rats. Reprod Toxicol. 2007;23(4):480-5.
20. Ochiai T, Nakajima K, Nagata M, Hori S, Asano T, Isono K. Studies of the induction and maintenance of a long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 1987;44(6):734-8.
21. Nepomuceno F, Las Casas L, Peters VM, Guerra MO. Desenvolvimento embrionário em ratas tratadas com Hipericum perforatum durante o período de implantação. Braz J Pharmacogn. 2005;15(3):224-8.
22. Nataraj SK, Puvvada PK, Badami S, Patil SB, Kannan E, Thillainayagam S, et al. Pre-coital and post-coital anti-implantation and abortifacient activities of Aristolachia bracteolata Lam. Aaerial parts. J Nat Med. 2007;61(3):302-6.
23. OECD. Guideline for the testing of chemicals - No. 414: Prenatal Developmental Toxicity Study. Paris: Organization for Economic Co-operation and Development; 2001.
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite. Guideline S5(R2): Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility [Internet]. 2005. [cited 2008 Jun 19]. p.14. Available from: http://www.ich.org/LOB/media/MEDIA498.pdf
25. Yao M, Ritchie HE, Brown-Woodman PD. A developmental toxicity-screening test of valerian. J Ethnopharmacol. 2007; 113(2):204-9.